Robert Coffin
Founder at REPLIMUNE GROUP, INC.
Net worth: 11 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philip Astley-Sparke | M | 51 |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | 9 years |
| Sushil Patel | M | 52 | 3 years | |
| Dieter Weinand | M | 63 | 6 years | |
| Paolo Pucci | M | 63 | 4 years | |
| Joseph Slattery | M | 59 | 7 years | |
| Hyam Levitsky | M | 66 | 6 years | |
| Tyler Jacks | M | 63 | 12 years | |
| Eric Morgan Yeatman | M | 61 |
Imperial College London
| 38 years |
| Kapil Dhingra | M | 64 | 7 years | |
| Christy Oliger | F | 54 | 3 years | |
| Andrew Schwendenman | M | 47 | 4 years | |
| Veleka Peeples-Dyer | F | 52 | 1 years | |
| Emily Hill | F | 44 | 1 years | |
| Arleen Goldenberg | F | - | - | |
| Konstantinos Xynos | M | 57 | 2 years | |
| Christopher Sarchi | M | 55 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen A. Gorgol | M | 65 |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | 6 years |
| Jean Franchi | F | 57 | 4 years | |
| Pamela Esposito | M | 50 |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | 11 years |
| Hugo Slootweg | M | 53 |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | 17 years |
| Kevin Sharer | M | 76 | 20 years | |
| David W. Beier | M | 75 | 10 years | |
| Colin Love | M | 65 |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | 23 years |
| George Morrow | M | 72 | 10 years | |
| Howard Goldsweig | M | - |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | 5 years |
| James Daly | M | 63 | 9 years | |
| Kamtorn Sila-on | M | 54 |
Imperial College London
| 4 years |
| David McShane | M | - |
Imperial College London
| 7 years |
| Anne Marie Woodland | F | - |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | 10 years |
| Mohammad Amin Liew bin Abdullah | M | 61 |
Imperial College London
| 7 years |
| Wendy Aritenang Yazid | M | 69 |
Imperial College London
| 4 years |
| Raymond C. Jordan | M | 70 | 7 years | |
| Marco Renoldi | M | 67 | 3 years | |
| Annette L. Such | F | 55 | - | |
| Laurie Stelzer | F | 56 | 2 years | |
| Yon-Ho Chong | M | - |
Imperial College London
| 9 years |
| Alan McLean | M | - |
Imperial College London
| 6 years |
| Frederick Gluck | M | 88 | 13 years | |
| Jean-Sébastien Cleiftie | M | 50 |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | - |
| Otello Stampacchia | M | 55 | 7 years | |
| Tanya Lewis | F | 53 | 4 years | |
| David S. Latchman | M | - |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | - |
| Jason Rhodes | M | 54 | 7 years | |
| Nigel Laurie Lee | M | 57 |
Imperial College London
| 1 years |
| Alexandre Quirici | M | - |
Imperial College London
| 3 years |
| João Afonso Ramalho Sopas Pereira Bento | M | 63 |
Imperial College London
| 3 years |
| Ian C. Lennon | M | - |
Imperial College London
| 3 years |
| Niaz Haider | M | - |
Imperial College London
| 3 years |
| Imoni L. Akpofure | F | - |
Imperial College London
| 4 years |
| Robin Hargrove | M | 58 |
Imperial College London
| 4 years |
| Alain Michaelis | M | 57 |
Imperial College London
| 4 years |
| Agus Hasan Reksoprodjo | M | 61 |
Imperial College London
| 3 years |
| Chi Wai Leung | M | 56 |
Imperial College London
| 4 years |
| Ihsan Jawad | M | - |
Imperial College London
| 4 years |
| Natasha Foong | F | - |
Imperial College London
| 1 years |
| Sharifuddin Bin Md. Zaini Al-manaf | M | 54 |
Imperial College London
| 4 years |
| Olu Odugbemi | M | - |
Imperial College London
| 1 years |
| Paul Dentskevich | M | - |
Imperial College London
| 4 years |
| Hironori Higashide | M | - |
Imperial College London
| 2 years |
| Ahmad Bahai | M | 61 |
Imperial College London
| 1 years |
| Sotirios Hadjimichael | M | 64 |
Imperial College London
| 3 years |
| Aaqib Mirza | M | - |
Imperial College London
| 4 years |
| Yewande Awe | M | - |
Imperial College London
| 2 years |
| Justin Leung | M | 56 |
Imperial College London
| 4 years |
| David Syriani | M | - |
Imperial College London
| 4 years |
| Amin Elkholy | M | - |
Imperial College London
| 4 years |
| D'Souza Kevin | M | - |
Imperial College London
| 4 years |
| Ravinder Dhaliwal | M | - |
Imperial College London
| 3 years |
| David O'Reilly | M | 58 |
Imperial College London
| 3 years |
| Paul Skipworth | M | 56 |
Imperial College London
| 4 years |
| Dimitrios Vidakis | M | - |
Imperial College London
| - |
| Sarah A. Hedger | F | 52 |
Imperial College London
| 1 years |
| Bernard Factor | M | - |
Imperial College London
| 4 years |
| Chi Man Cheung | M | 56 |
Imperial College London
| 4 years |
| Wai Keung Yuen | M | 60 |
Imperial College London
| 4 years |
| Angus S. J. Fraser | M | - |
Imperial College London
| 5 years |
| Helen Alexander | F | 62 |
Imperial College London
| 4 years |
| Brahmal Vasudevan | M | 55 |
Imperial College London
| 3 years |
| Thomas Michael Hughes | M | 56 |
Imperial College London
| 4 years |
| Mahendra Deonarain | M | - |
Imperial College London
| 4 years |
| Andrew Sean Holmes | M | 60 |
Imperial College London
| 3 years |
| Iain Lindsay | M | - |
Imperial College London
| 4 years |
| Mick Cardew-Hall | M | - |
Imperial College London
| 4 years |
| Andrew Creeke | M | - |
Imperial College London
| 3 years |
| Tony Day | M | - |
Imperial College London
| 4 years |
| Samuel Paul Oliver Carew-Jones | M | 49 |
Imperial College London
| 4 years |
| Cheong Thard Hoong | M | 55 |
Imperial College London
| 4 years |
| Alexander Fortescue | M | 56 |
Imperial College London
| 3 years |
| Chi Ho Wong | M | - |
Imperial College London
| 4 years |
| Hua Shan Wang | M | 62 |
Imperial College London
| 3 years |
| John Coleman O'Donohue | M | 60 |
Imperial College London
| 2 years |
| Erik Urnes | M | 53 |
Imperial College London
| 3 years |
| Siew Ge Ng | M | 68 |
Imperial College London
| 1 years |
| Jonathan Faiman | M | 55 |
Imperial College London
| 4 years |
| Sam Rahman | M | - |
Imperial College London
| 1 years |
| Chuan Poh Lim | M | 70 |
Imperial College London
| 1 years |
| Michael Shipman | M | - |
Imperial College London
| 3 years |
| Kee Way Lim | M | 58 |
Imperial College London
| 1 years |
| Noel C. Machingawuta | M | - |
Imperial College London
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 66 | 66.67% |
| United States | 36 | 36.36% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert Coffin
- Personal Network
